Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Recruiting now · Phase 2

Conditions studied: Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired

In brief

The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

Key facts

Study ID
NCT06976476
Run by
Memorial Sloan Kettering Cancer Center
People needed
100
Starts
2025-05-08
Expected to finish
2029-05-08
Last updated by the study team
2026-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.